Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with ...
Is Efficacious in Human Ovarian and Kidney Cancer Models DXd ADC is a novel ADC therapeutic designed with a potent DNA topoisomerase I inhibitor exatecan delivative. Raludotatug deruxtecan (R-DXd) is ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...
The biotech is prioritizing its exatecan-based platform for solid tumors. Exatecan, a potent inhibitor of topoisomerase I, is at the center of ADC’s next wave of candidates. The biotech has ...
La investigación continúa. De hecho, como ha demostrado el estudio "Destiny Breast 06", presentado este año, trastuzumab-deruxtecan mejora resultados en cáncer de mama metastásico en ...
Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...
MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's protocol amendment proposal to study anticancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback